We break through tumor defenses to enable cancer cures.


A solid tumor is built like a fortress with defenses that prevent cancer therapies from reaching the cancer cells they are meant to kill. CytImmune has developed a nanomedicine platform that can successfully get into the tumor and break down its defenses. Like a Trojan horse, the nanomedicines built on CytImmune’s Aurimune platform evade detection as they safely move through the body and use the tumor’s unique biology to gain entrance into the tumor. Once inside, they unleash their payload, disrupting the tumor’s blood vessel architecture and enabling other cancer therapies to reach and kill the cancer cells.

Tumor-Targeted Trojan Horse

  • Aurimune can shield toxic substances like TNF from the body. When the Aurimune nanomedicine reaches the tumor, it is sized to pass through the abnormally large gaps that are found in tumor blood vessels.
  • The TNF on the Aurimune nanomedicine acts like an anchor and binds strongly to the tumor’s blood vessels.
  • In a short period of time, the concentration of Aurimune inside the tumor increases and only trace amounts can be found in the rest of the body.
Aliquam pulvinar neque tristique enim rutrum, ac blandit orci dignissim aliquam sed consectetur massa, et tempor tellus quisque vulputate, orci id adipiscing tincidunt, massa tortor luctus lectus, a sodales magna est sit amet urna.
- Dr. John Doe, MD
Montefiore Medical Center


CytImmune created Aurimune to make a quantum leap forward in the technology available to safely and effectively deliver a range of anti-cancer therapies into tumors.

Gold-based Technology

At the center of the Aurimune nanomedicine is a precisely sized gold particle. Sizing is optimized to take advantage of the gaps in the leaky tumor blood vessels. Gold has low toxicity and regulators understand its safety profile, since it has been used therapeutically in humans for decades.

PolyEthylene Glycol

PolyEthylene Glycol (PEG) is a water-absorbing molecule that covers the gold particle like tiny hairs and is key to the stealthy nature of the Aurimune product. PEG attracts and holds a water shield around the nanomedicine as it passes through the body’s blood vessels and vital organs. This water shield hides the toxic anti-cancer agents until they reach the tumor, reducing toxicity and allowing higher targeted doses of chemotherapy.

Tumor Necrosis Factor

Tumor Necrosis Factor (TNF) breaks down the blood vessel architecture inside tumors. This makes the cancer cells inside the tumor vulnerable to anti-cancer agents. It has been successfully used as an anticancer agent in Europe in a procedure that involves administering TNF and follow-on chemotherapy locally to a tumor on an arm or leg. TNF and chemotherapy are injected into a blood vessel, which has been isolated from the rest of the body, circumventing TNF toxicity by not allowing the TNF to reach vital organs. With this procedure, TNF followed by chemotherapy, tumor response rates of 85% are routinely observed. Aurimune is the only technology that has ever delivered TNF systemically to tumors with little to no toxicity.

Proprietary Linkers

CytImmune developed patented linker technology to attach small molecule, anti-cancer agents directly to the Aurimune nanomedicine. These linkers are unique in that they can be adjusted to work with a variety of agents targeting multiple tumor types.


Clinical Trials


A first generation Aurimune platform nanomedicine, CYT-6091 carries TNF into tumors to disrupt their blood vessels and enable follow-on chemotherapy to penetrate the tumor and kill the cancer cells inside. In a successful Phase I clinical trial, CYT-6091 safely delivered what would have been a toxic but highly effective dose of the anti-cancer agent TNF to patients; dose levels were three times the previous maximum tolerated dose. Tissue samples, taken 24 hours after CYT-6091 administration, showed that the nanomedicine had concentrated inside tumor tissues, not inside surrounding healthy tissue.

A Phase II clinical trial will treat non small-lung cancer patients in combination with standard of care, second line therapy. Additional details related to the Phase II trial will be announced during the summer of 2014.

Preclinical Studies


A second generation Aurimune platform nanomedicine, CYT-21000 carries Taxol (paclitaxel) in addition to TNF. Aurimune is currently the only nanotechnology that has been able to simultaneously deliver a biologic, TNF and a small molecule therapeutic, Taxol, carried by the same nanoparticle.


AstraZeneca Partnership

CytImmune is currently working with the AstraZeneca’s Oncology Innovative Medicines Unit to examine the viability of delivering an AstraZeneca anti-cancer therapy into solid tumors using the Aurimune nanomedicine platform.

Other CytImmune Investigations

CytImmune has successfully linked other anti-cancer agents to the Aurimune platform. These include:

  • Interferon (CYT-61000)
  • Gemcitabine (CYT-71000)


The Aurimune nanomedicine platform offers the potential to enable and/or expand the clinical benefit of a variety of toxic anti-cancer therapies including those that treat multiple types of solid tumors -- either as monotherapies or in combination with existing standards of care. Aurimune functions independent of tumor-specific biochemistry; therefore it does not depend on the type of cancer treated.

Aurimune is the only clinical stage tumor-targeted product that can carry both biologics and small molecule therapeutics.

CytImmune has experience with numerous therapeutic classes of drug enabling them to bind to the Aurimune platform.

CytImmune has a successful track record working with other institutions to integrate existing anti-cancer agents onto the Aurimune nanomedicine, rescuing molecules whose systemic toxicity has stifled clinical development.


CytImmune and AstraZeneca holding conference call for important announcement
Tuesday, May 27, 2014
CytImmune unveils a completely redesigned brand identity
Sunday, May 25, 2014
CytImmune and MIT to Establish a Joint Venture to Revolutionize Health Startups
Wednesday, May 21, 2014
CytImmune eradicated tumors in a revolutionary way, enters Phase II
Wednesday, May 21, 2014
CytImmune and AstraZeneca to Research Potential New NanoMedicine for Cancer
Thursday, December 27, 2012
Gold Particles could deliver cancer drugs
Monday, December 24, 2012


Founded in 1988, CytImmune has transitioned from a successful diagnostics company into a clinical stage nanomedicine company with a core focus on the discovery, development and commercialization of multifunctional, tumor-targeted therapies.

CytImmune is a global leader in the field of nanomedicine with the successful completion of a Phase I clinical trial of CYT-6091 — the first in a series of products based on the CytImmune’s Aurimune nanomedicine platform. The company has more than 60 issued and pending patents for its colloidal gold nanotechnology in the United States, European Union, Japan and Canada.


Lawrence Tamarkin, Ph.D.
Co-Founder, President & CEO
Giulio F. Paciotti, Ph.D.
Co-Founder, Chief Scientific Officer
Mitchell S. Marder
Executive Vice President, Corporate Development and Chief Legal Officer
Gary Rosenfeld
Chief Financial Officer


Lawrence Tamarkin, Ph.D.
Chairman, President & CEO, CytImmune
Robert Ashton, MD
Thoracic surgeon and consultant to financial institutions
Neal Cohen
President & COO, APCO Worldwide
John Holaday, Ph.D.
President & CEO, QRxPharma
Ken Itani
Group General Manager, Itanis International, Inc.
Marc Stanley
Former Acting Deputy Director, National Institute of Standards and Technology
Norman Zober, Ph.D.
President & CEO, NHM, advisory firm to venture capital companies


Steven K. Libutti, M.D., FACS
Director, Montefiore Einstein Center for Cancer Care
Prof. Alexander M.M. Eggermont, M.D./Ph.D
Director General, Cancer Institute Gustave Roussy


For additional information on CytImmune or the Aurimune nanomedicine platform, contact us at:

CytImmune Sciences
15010 Broschart Road
Rockville, MD 20850

Phone: (301) 825-3041